Bi-level Positive Airway Pressure (BiPAP) Devices Market to Reach USD 3.70 Billion by 2033 | North America Holds 41.9% Market Share | Key Players: ResMed, Philips Respironics, Fisher & Paykel Healthcare

The global Bi-level Positive Airway Pressure (BiPAP) Devices market was valued at USD 2.43 billion in 2025 and is projected to reach USD 3.70 billion by 2033, growing at a CAGR of 5.5% during the forecast period from 2026 to 2033. The market presents a steady growth opportunity driven by the rising prevalence of obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), obesity hypoventilation syndrome, and other respiratory disorders requiring non-invasive ventilation. BiPAP devices are increasingly adopted across hospitals, sleep laboratories, emergency care settings, and home healthcare environments due to their ability to deliver two levels of positive airway pressure, improving breathing comfort, reducing respiratory effort, and enhancing patient outcomes. Growing awareness of sleep-related breathing disorders, increasing diagnosis rates, and expanding geriatric populations are further supporting market growth.

The market is further benefiting from advancements in portable respiratory care technologies, smart connectivity, cloud-based patient monitoring, and artificial intelligence-enabled therapy management. Manufacturers are focusing on developing compact, quieter, and user-friendly BiPAP systems with integrated humidification, wireless data transmission, remote compliance monitoring, and personalized pressure adjustment features to improve treatment adherence. Rising adoption of home healthcare services, favorable reimbursement policies in developed markets, and increasing investments in digital respiratory care solutions are creating additional growth opportunities. Furthermore, the growing burden of chronic respiratory diseases, expanding telemedicine adoption, and increasing demand for non-invasive ventilation following critical care and post-acute recovery are strengthening market expansion. As healthcare systems continue to prioritize early respiratory intervention and home-based disease management, the Bi-level Positive Airway Pressure (BiPAP) Devices market is expected to offer strong long-term growth potential and an attractive business landscape for medical device manufacturers, healthcare providers, and investors worldwide.

Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID):https://www.datamintelligence.com/download-sample/bi-level-positive-airway-pressure-devices-market?sai-v

Key Developments
July 2026: The United States strengthened respiratory care innovation as ResMed Inc. expanded its next-generation BiPAP device portfolio with AI-enabled therapy monitoring, cloud connectivity, and enhanced patient comfort features for sleep apnea and chronic respiratory disease management.

June 2026: Europe accelerated the adoption of connected respiratory care as Löwenstein Medical Technology introduced advanced non-invasive ventilation (NIV) and BiPAP systems with improved humidification, remote monitoring, and personalized therapy capabilities.

May 2026: United States-based Philips Respironics expanded digital respiratory care initiatives by enhancing connectivity and remote patient management features across its non-invasive ventilation solutions, supporting long-term home care and hospital-based respiratory therapy.

April 2026: Japan strengthened respiratory healthcare infrastructure as Fukuda Denshi Co., Ltd. advanced the development of non-invasive ventilation systems designed to improve treatment outcomes for patients with chronic obstructive pulmonary disease (COPD) and other respiratory disorders.

March 2026: China increased investments in domestic respiratory medical device manufacturing, expanding production of BiPAP and non-invasive ventilation devices to address the growing burden of sleep-disordered breathing and chronic respiratory diseases.

February 2026: North America witnessed growing collaborations between healthcare providers, sleep clinics, and respiratory device manufacturers to improve access to home-based BiPAP therapy through digital monitoring and telehealth-enabled patient management.

January 2026: The Asia-Pacific region experienced increased adoption of BiPAP devices as hospitals and home healthcare providers expanded non-invasive respiratory support services driven by the rising prevalence of sleep apnea, COPD, and aging populations.

Key Players
ResMed | Philips Respironics | Fisher & Paykel Healthcare | Medtronic plc | Drägerwerk AG & Co. KGaA | Getinge AB | Hamilton Medical | Breas Medical | Löwenstein Medical | DeVilbiss Healthcare | Others

Key Highlights
ResMed - Holds a 27.8% share, driven by its leadership in non-invasive ventilation, advanced BiPAP devices, connected respiratory care platforms, and extensive global distribution network.

Philips Respironics - Holds a 22.4% share, supported by its comprehensive sleep and respiratory care portfolio, innovative BiPAP technologies, and integrated digital patient monitoring solutions.

Fisher & Paykel Healthcare - Holds a 15.7% share, strengthened by its expertise in humidification technologies, non-invasive ventilation systems, and continuous innovation in respiratory care.

Medtronic plc - Holds a 9.2% share, fueled by its critical care ventilation portfolio, advanced respiratory support systems, and strong hospital presence worldwide.

Drägerwerk AG & Co. KGaA - Holds a 6.8% share, supported by its intensive care ventilators, respiratory monitoring technologies, and broad critical care product portfolio.

Getinge AB - Holds a 5.3% share, driven by its ICU ventilation systems, life-support technologies, and comprehensive critical care solutions.

Hamilton Medical - Holds a 4.2% share, strengthened by its intelligent ventilation technologies, adaptive respiratory support systems, and strong adoption in intensive care settings.

Breas Medical - Holds a 3.4% share, supported by its home respiratory care devices, portable BiPAP systems, and focus on long-term ventilation solutions.

Löwenstein Medical - Holds a 2.8% share, fueled by its sleep therapy and respiratory care technologies, high-performance ventilation systems, and expanding international presence.

DeVilbiss Healthcare - Holds a 1.9% share, driven by its respiratory therapy equipment, home healthcare solutions, and established distribution network.

Others - Hold a combined 0.5% share, comprising regional respiratory device manufacturers, emerging non-invasive ventilation companies, and specialized home respiratory care providers.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=bi-level-positive-airway-pressure-devices-market?sai-v

Market Drivers
Increasing prevalence of chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), obesity hypoventilation syndrome, and other respiratory disorders is significantly driving growth of the Bi-level Positive Airway Pressure (BiPAP) Devices market worldwide.

Growing aging population and rising incidence of chronic respiratory diseases are accelerating demand for non-invasive ventilation solutions across hospitals, sleep centers, and home healthcare settings.

Increasing preference for non-invasive respiratory support over invasive mechanical ventilation is strengthening adoption of BiPAP devices for acute and chronic respiratory care.

Advancements in portable BiPAP systems, intelligent pressure adjustment algorithms, wireless connectivity, and remote patient monitoring technologies are improving treatment effectiveness, patient comfort, and therapy adherence.

Expansion of home healthcare services and increasing demand for home-based respiratory care are supporting wider adoption of BiPAP devices among patients with long-term respiratory conditions.

Growing awareness of sleep-related breathing disorders, early diagnosis, and timely treatment is increasing utilization of BiPAP therapy in sleep medicine.

Rising investments by medical device manufacturers, healthcare providers, and governments in respiratory care technologies and digital health infrastructure are supporting market growth.

Increasing integration of cloud-based therapy management, telehealth platforms, and AI-enabled respiratory monitoring solutions is further propelling the global Bi-level Positive Airway Pressure (BiPAP) Devices market.

Industry Developments
Rapid advancement in portable and compact BiPAP devices, AI-powered pressure optimization technologies, and smart connectivity features improving patient comfort, therapy compliance, and clinical outcomes.

Increasing adoption of connected respiratory care solutions integrating BiPAP devices with mobile applications, cloud platforms, and remote patient monitoring systems supporting personalized treatment.

Growing investments in lightweight device designs, quieter motors, enhanced humidification systems, and advanced mask technologies accelerating innovation across the BiPAP ecosystem.

Expansion of collaborations among medical device manufacturers, healthcare providers, sleep clinics, and home healthcare companies driving development of comprehensive respiratory care solutions.

Rising integration of artificial intelligence, digital health platforms, and predictive analytics enhancing therapy management, patient monitoring, and clinical decision-making.

Strategic product launches, regulatory approvals, acquisitions, and geographic expansion initiatives by leading respiratory care companies supporting global market growth and wider accessibility.

Continuous improvements in airflow algorithms, battery technology, device portability, user interfaces, and data management systems enhancing reliability, ease of use, and long-term treatment effectiveness.

Regional Insights
North America 41.9% share: Leads the market due to high prevalence of sleep apnea and COPD, advanced healthcare infrastructure, favorable reimbursement policies, widespread adoption of home respiratory care, and the presence of leading respiratory device manufacturers.

Europe 28.3% share: Strong market presence driven by increasing awareness of respiratory disorders, expanding home healthcare services, supportive reimbursement frameworks, and growing adoption of non-invasive ventilation technologies.

Asia Pacific 23.4% share: Fastest-growing region supported by rising respiratory disease burden, expanding healthcare infrastructure, increasing healthcare expenditure, and growing adoption of advanced respiratory care technologies across China, Japan, India, and South Korea.

Latin America 3.8% share: Growth supported by improving access to respiratory care, increasing diagnosis of sleep-related breathing disorders, and expanding home healthcare services, particularly in Brazil and Mexico.

Middle East & Africa 2.6% share: Emerging growth driven by rising prevalence of chronic respiratory diseases, improving healthcare infrastructure, increasing investments in respiratory care, and growing awareness of non-invasive ventilation solutions.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/bi-level-positive-airway-pressure-devices-market?sai-v

Key Segments
➥ By Technology/Modality

PROTACs: Represents the dominant segment, driven by extensive clinical research, strong pharmaceutical investments, and broad therapeutic potential.

Molecular Glues: Represents a rapidly growing segment, supported by increasing discovery of novel protein degradation mechanisms and expanding clinical pipelines.

Degronimids: Represents a significant segment, fueled by advancements in cereblon-based targeted protein degradation therapies.

LYTACs: Represents a growing segment, driven by their ability to target extracellular and membrane-bound proteins previously considered undruggable.

AUTACs: Represents a promising segment, supported by increasing research into autophagy-mediated protein degradation.

ATTECs: Represents a growing segment, fueled by expanding applications in neurodegenerative disease research.

DUB Inhibitors: Represents a significant segment, driven by increasing focus on regulating ubiquitin-mediated protein degradation pathways.

SERD-Based Degraders: Represents a substantial segment, supported by growing development of targeted therapies for hormone-driven cancers.

BET Degraders: Represents a major segment, fueled by increasing oncology research targeting epigenetic regulators.

Others: Represents a moderate segment, supported by continuous innovation in next-generation targeted protein degradation technologies.

➥ By Target Protein Class

Transcription Factors: Represents the dominant segment, driven by increasing efforts to target previously undruggable cancer-related proteins.

Nuclear Hormone Receptors: Represents a significant segment, supported by growing applications in breast and prostate cancer therapies.

Epigenetic Regulators: Represents a major segment, fueled by increasing research into chromatin-modifying proteins.

Kinases: Represents a substantial segment, driven by expanding development of targeted therapies for cancer and inflammatory diseases.

Scaffold Proteins: Represents a growing segment, supported by advances in protein degradation technologies.

Misfolded/Aggregated Proteins: Represents a rapidly growing segment, fueled by increasing research in neurodegenerative disorders.

Others: Represents a moderate segment, driven by expanding discovery of novel therapeutic targets.

➥ By Therapeutic Area

Oncology: Represents the dominant segment, driven by the extensive development of targeted protein degraders for solid tumors and hematological malignancies.

Immunology/Inflammatory: Represents a significant segment, supported by increasing research into autoimmune and inflammatory diseases.

Neurology: Represents a rapidly growing segment, fueled by advancements in therapies for Alzheimer's, Parkinson's, and Huntington's diseases.

Ophthalmology: Represents a growing segment, driven by emerging applications in retinal and ocular disorders.

Respiratory: Represents a moderate segment, supported by ongoing research into inflammatory lung diseases.

Infectious: Represents a developing segment, fueled by efforts to target viral and bacterial proteins.

Rare/Genetic: Represents a significant segment, driven by increasing focus on precision medicine.

Metabolic: Represents a growing segment, supported by research into obesity and metabolic disorders.

Others: Represents a moderate segment, supported by expanding therapeutic applications.

➥ By Route of Administration

Oral: Represents the dominant segment, driven by improved patient compliance and ease of administration.

IV: Represents a significant segment, supported by hospital-based treatment protocols and biologic therapies.

SC: Represents a growing segment, fueled by increasing development of self-administered therapies.

Intravitreal: Represents a niche segment, supported by ophthalmology applications.

Others: Represents a moderate segment, driven by specialized drug delivery methods.

➥ By Stage of Development

Discovery: Represents the largest segment, driven by a broad pipeline of novel targeted protein degradation candidates.

Preclinical & Clinical Development: Represents a rapidly growing segment, supported by increasing investments and strategic collaborations.

Approved: Represents a developing segment, fueled by the commercialization of first-generation targeted protein degradation therapies.

➥ By End User

Hospitals: Represents a significant segment, driven by clinical adoption of advanced targeted therapies.

Clinics: Represents a growing segment, supported by expanding outpatient treatment services.

Research/Academic Laboratories: Represents the dominant segment, fueled by extensive research and early-stage drug discovery.

Pharma/Biotech: Represents a major segment, driven by substantial R&D investments and pipeline expansion.

CROs: Represents a significant segment, supported by increasing outsourcing of drug development activities.

➥ By Age Group

Children & Adolescents: Represents a moderate segment, supported by research into rare genetic disorders.

Adults: Represents the dominant segment, driven by the high prevalence of cancer and chronic diseases.

Geriatric: Represents a rapidly growing segment, fueled by increasing incidence of age-related disorders.

➥ By Degradation Pathway

UPS (Ubiquitin-Proteasome System): Represents the dominant segment, driven by widespread use of PROTAC-based therapies.

Autophagy-Lysosome: Represents a significant segment, supported by increasing development of AUTAC and ATTEC technologies.

Endosome-Lysosome: Represents a growing segment, fueled by advancements in LYTAC technology.

Chaperone-Mediated: Represents a developing segment, supported by ongoing translational research.

Others: Represents a moderate segment, driven by emerging degradation mechanisms.

➥ By Protein Localization

Nuclear: Represents the dominant segment, driven by extensive targeting of transcription factors and nuclear receptors.

Cytoplasmic: Represents a significant segment, supported by broad applications in oncology and inflammatory diseases.

Membrane-Bound: Represents a rapidly growing segment, fueled by advances in LYTAC-based therapeutics.

Extracellular: Represents a growing segment, driven by increasing focus on previously inaccessible therapeutic targets.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.